{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:41:48Z","timestamp":1792467708570,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Fasinumab, a newly developed anti-nerve growth factor monoclonal antibody, has been evaluated in clinical trials for its potential to alleviate symptoms in osteoarthritis patients. This meta-analysis evaluates the efficacy and safety of different Fasinumab dosages compared with placebo in patients with osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed (MEDLINE), Cochrane CENTRAL, ClinicalTrials.gov, and Google Scholar were searched for double-blinded RCTs comparing Fasinumab with placebo till December 2025. Primary outcomes were WOMAC pain, WOMAC function, and Patient Global Assessment (PGA) scores. Secondary outcomes included safety profile such as Adjudicated Arthropathy, Adverse events, serious adverse events, all-cause mortality. Cochrane Risk of Bias 2 was used for quality assessment. A random effects model was used for analysis, with subgrouping by dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six RCTs, involving 9,429 participants, were included. All trials included had a low risk of bias. At 16 weeks, 1\u00a0mg Subcutaneous (SC) Every four weeks (Q4W), 1\u00a0mg SC Every eight weeks (Q8W), and 3\u00a0mg SC Q4W showed a greater statistically significant reduction in WOMAC pain and function scores compared to placebo. However, according to minimal clinically important differences (MCIDs), only 1\u00a0mg SC Q4W and 3\u00a0mg SC Q4W may provide clinically meaningful reductions in WOMAC pain ([MD: -1.05, (95% C.I. -1.32 to -0.78),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001, I\u00b2=28%] and [MD: -1.16, (95% C.I. -1.58 to -0.75),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001, I\u00b2=0%], respectively) and function scores ([-1.05 (95% C.I. -1.32 to -0.79),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001, I\u00b2=20%] and [MD: -1.24, (95% C.I. -1.65 to -0.83),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001, I\u00b2=0%], respectively) more than placebo; however, the confidence intervals include effects smaller than the MCID threshold, limiting certainty regarding clinically meaningful benefit. A 1\u00a0mg SC Q4W dosage regimen is favored over a placebo in improving PGA scores at 16 weeks. Further, Fasinumab use may increase the risk of adverse events, including Joint-replacement surgery and Adjudicated Arthropathy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although select fasinumab regimens demonstrated statistically significant reductions in WOMAC pain, function, and PGA scores at 16 weeks, confidence interval overlaps with conservative MCID thresholds limit certainty regarding clinically meaningful efficacy. Additionally, treatment may carry increased risks, including adjudicated arthropathy.In addition, osteoarthritis is a chronic disease, and these short-term efficacy outcomes may not reflect long-term treatment effectiveness. These findings are based on trials assessed as having an overall low risk of bias. Further research is needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12891-026-10271-8","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:53:01Z","timestamp":1784875981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fasinumab for osteoarthritis: a systematic review and meta-analysis of efficacy and safety"],"prefix":"10.1186","volume":"27","author":[{"given":"Muhammad Sohaib","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wania","family":"Moeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umm E Salma Shabbar","family":"Banatwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ashad Ahmed","family":"Fatmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Muneeb","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashir","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Talal","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badaruddin","family":"Sahito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-2030","authenticated-orcid":false,"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"10271_CR1","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3390\/ijms22052619","volume":"22","author":"S Jang","year":"2021","unstructured":"Jang S, Lee K, Ju JH. Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee. IJMS. 2021;22:2619. https:\/\/doi.org\/10.3390\/ijms22052619.","journal-title":"IJMS"},{"key":"10271_CR2","unstructured":"Sen R, Hurley JA. Osteoarthritis. In: StatPearls. StatPearls Publishing, Treasure Island (FL). 2024. Available from. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482326\/."},{"key":"10271_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.mcna.2019.10.007","volume":"104","author":"B Abramoff","year":"2020","unstructured":"Abramoff B, Caldera FE. Osteoarthritis. Med Clin North Am. 2020;104:293\u2013311. https:\/\/doi.org\/10.1016\/j.mcna.2019.10.007.","journal-title":"Med Clin North Am"},{"key":"10271_CR4","unstructured":"The Burden of Musculoskeletal Diseases in the United States. Fourth Edition. In: BMUS: The Burden of Musculoskeletal Diseases in the United States. https:\/\/www.boneandjointburden.org\/fourth-edition."},{"key":"10271_CR5","unstructured":"March L, Cross M, Lo C, et al. Osteoarthritis: A Serious Disease. Submitted to the U.S. Food and Drug Administration; 2016. https:\/\/oarsi.org\/sites\/oarsi\/files\/library\/2018\/pdf\/oarsi_white_paper_oa_serious_disease121416_1.pdf. Accessed 17 Jan 2025."},{"key":"10271_CR6","doi-asserted-by":"publisher","first-page":"e067545","DOI":"10.1136\/bmjopen-2022-067545","volume":"13","author":"G Coates","year":"2023","unstructured":"Coates G, Clewes P, Lohan C, et al. Health economic impact of moderate-to-severe chronic pain associated with osteoarthritis in England: a retrospective analysis of linked primary and secondary care data. BMJ Open. 2023;13:e067545. https:\/\/doi.org\/10.1136\/bmjopen-2022-067545.","journal-title":"BMJ Open"},{"key":"10271_CR7","doi-asserted-by":"publisher","unstructured":"Yu H, Huang T, Lu WW et al. Osteoarthritis Pain. IJMS. 2022;23:4642. https:\/\/doi.org\/10.3390\/ijms23094642.","DOI":"10.3390\/ijms23094642"},{"key":"10271_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4081\/reumatismo.2014.766","volume":"66","author":"F Salaffi","year":"2014","unstructured":"Salaffi F, Ciapetti A, Carotti M. The sources of pain in osteoarthritis: a pathophysiological review. Reumatismo. 2014;66:57\u201371. https:\/\/doi.org\/10.4081\/reumatismo.2014.766.","journal-title":"Reumatismo"},{"key":"10271_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/5706359","volume":"2016","author":"S Takano","year":"2016","unstructured":"Takano S, Uchida K, Miyagi M, et al. Nerve Growth Factor Regulation by TNF- \u03b1 and IL-1 \u03b2 in Synovial Macrophages and Fibroblasts in Osteoarthritic Mice. J Immunol Res. 2016;2016:1\u20138. https:\/\/doi.org\/10.1155\/2016\/5706359.","journal-title":"J Immunol Res"},{"key":"10271_CR10","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1038\/s41598-021-83025-2","volume":"11","author":"H Bansal","year":"2021","unstructured":"Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. Sci Rep. 2021;11:3971. https:\/\/doi.org\/10.1038\/s41598-021-83025-2.","journal-title":"Sci Rep"},{"key":"10271_CR11","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.3390\/cells10102572","volume":"10","author":"R Vaiciuleviciute","year":"2021","unstructured":"Vaiciuleviciute R, Bironaite D, Uzieliene I, et al. Cardiovascular Drugs and Osteoarthritis: Effects of Targeting Ion Channels. Cells. 2021;10:2572. https:\/\/doi.org\/10.3390\/cells10102572.","journal-title":"Cells"},{"key":"10271_CR12","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/AJP.0000000000000986","volume":"37","author":"B Zhang","year":"2021","unstructured":"Zhang B, Tian X, Qu Z, et al. Relative Efficacy and Safety of Tanezumab for Osteoarthritis. Clin J Pain. 2021;37:914\u201324. https:\/\/doi.org\/10.1097\/AJP.0000000000000986.","journal-title":"Clin J Pain"},{"key":"10271_CR13","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/ar4044","volume":"14","author":"WP Maksymowych","year":"2012","unstructured":"Maksymowych WP, Russell AS, Chiu P, et al. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther. 2012;14:R206. https:\/\/doi.org\/10.1186\/ar4044.","journal-title":"Arthritis Res Ther"},{"key":"10271_CR14","unstructured":"Ellis CR, Azmat CE. Adalimumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557889\/."},{"key":"10271_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.joca.2022.11.005","volume":"31","author":"MJ Richard","year":"2023","unstructured":"Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthr Cartil. 2023;31:458\u201366. https:\/\/doi.org\/10.1016\/j.joca.2022.11.005.","journal-title":"Osteoarthr Cartil"},{"key":"10271_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1148\/radiol.2019190341","volume":"293","author":"AJ Kompel","year":"2019","unstructured":"Kompel AJ, Roemer FW, Murakami AM, Diaz LE, Crema MD, Guermazi A. Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Safe as We. Thought? Radiol. 2019;293:656\u201363. https:\/\/doi.org\/10.1148\/radiol.2019190341.","journal-title":"Thought? Radiol"},{"key":"10271_CR17","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.joca.2014.10.003","volume":"23","author":"TJ Schnitzer","year":"2015","unstructured":"Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthr Cartil. 2015;23:S8\u201317. https:\/\/doi.org\/10.1016\/j.joca.2014.10.003.","journal-title":"Osteoarthr Cartil"},{"key":"10271_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2147\/JPR.S65974","volume":"7","author":"PJ Tiseo","year":"2014","unstructured":"Tiseo PJ, Ren H, Mellis S. Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study. J Pain Res. 2014;7:523\u201330. https:\/\/doi.org\/10.2147\/JPR.S65974.","journal-title":"J Pain Res"},{"key":"10271_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.18632\/aging.202232","volume":"13","author":"Z Cao","year":"2020","unstructured":"Cao Z, Zhou J, Long Z, et al. Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs. Aging. 2020;13:1051\u201370. https:\/\/doi.org\/10.18632\/aging.202232.","journal-title":"Aging"},{"key":"10271_CR20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.pain.2014.03.018","volume":"155","author":"PJ Tiseo","year":"2014","unstructured":"Tiseo PJ, Kivitz AJ, Ervin JE, et al. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain. 2014;155:1245\u201352. https:\/\/doi.org\/10.1016\/j.pain.2014.03.018.","journal-title":"Pain"},{"key":"10271_CR21","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"10271_CR22","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"10271_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"10271_CR24","first-page":"2635","volume":"27","author":"EW Ehrich","year":"2000","unstructured":"Ehrich EW, Davies GM, Watson DJ, et al. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol. 2000;27:2635\u201341.","journal-title":"J Rheumatol"},{"key":"10271_CR25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.41012","volume":"71","author":"P Dakin","year":"2019","unstructured":"Dakin P, DiMartino SJ, Gao H, et al. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb\/III Double-Blind, Placebo\u2010Controlled, Randomized Clinical Trial. Arthritis Rheumatol. 2019;71:1824\u201334. https:\/\/doi.org\/10.1002\/art.41012.","journal-title":"Arthritis Rheumatol"},{"key":"10271_CR26","unstructured":"Regeneron P. A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip. clinicaltrials.gov. 2023. Available from. https:\/\/clinicaltrials.gov\/study\/NCT02683239."},{"key":"10271_CR27","unstructured":"Regeneron P. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee. clinicaltrials.gov. 2023. Available from. https:\/\/clinicaltrials.gov\/study\/NCT03691974."},{"key":"10271_CR28","unstructured":"Regeneron P. A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip. clinicaltrials.gov. 2022. Available from. https:\/\/clinicaltrials.gov\/study\/NCT03161093."},{"key":"10271_CR29","unstructured":"Mitsubishi Tanabe Pharma Corporation. A Phase 2\/3 (Placebo-Controlled, Double-Blind, Comparative) Study on MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain. clinicaltrials.gov. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03245008."},{"key":"10271_CR30","unstructured":"Regeneron P. Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip. clinicaltrials.gov. 2023. Available from. https:\/\/clinicaltrials.gov\/study\/NCT03304379."},{"key":"10271_CR31","first-page":"i","volume":"894","author":"Obesity","year":"2000","unstructured":"Obesity. preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i\u2013xii.","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10271_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/ard.16.4.494","volume":"16","author":"JH Kellgren","year":"1957","unstructured":"Kellgren JH, Lawrence JS. Radiological Assessment of Osteo-Arthrosis. Ann Rheum Dis. 1957;16:494\u2013502. https:\/\/doi.org\/10.1136\/ard.16.4.494.","journal-title":"Ann Rheum Dis"},{"key":"10271_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4103\/sja.sja_158_21","volume":"15","author":"H Sharma","year":"2021","unstructured":"Sharma H. Statistical significance or clinical significance? A researcher\u2019s dilemma for appropriate interpretation of research results. Saudi J Anaesth. 2021;15:431. https:\/\/doi.org\/10.4103\/sja.sja_158_21.","journal-title":"Saudi J Anaesth"},{"key":"10271_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2106\/JBJS.H.01602","volume":"91","author":"M Zlowodzki","year":"2009","unstructured":"Zlowodzki M, Bhandari M. Outcome Measures and Implications for Sample-Size Calculations. J Bone Joint Surg. 2009;91:35\u201340. https:\/\/doi.org\/10.2106\/JBJS.H.01602.","journal-title":"J Bone Joint Surg"},{"key":"10271_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/17512433.2020.1772052","volume":"13","author":"F Patel","year":"2020","unstructured":"Patel F, Hess DK, Maher DP. Anti-nerve growth factor antibodies for the treatment of low back pain. Expert Rev Clin Pharmacol. 2020;13:631\u20139. https:\/\/doi.org\/10.1080\/17512433.2020.1772052.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10271_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/BOR.0000000000000354","volume":"29","author":"RE Miller","year":"2017","unstructured":"Miller RE, Block JA, Malfait AM. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol. 2017;29(1):110\u20138. https:\/\/doi.org\/10.1097\/BOR.0000000000000354.","journal-title":"Curr Opin Rheumatol"},{"key":"10271_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/1479-5876-10-239","volume":"10","author":"L Aloe","year":"2012","unstructured":"Aloe L, Rocco ML, Bianchi P, et al. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012;10:239. https:\/\/doi.org\/10.1186\/1479-5876-10-239.","journal-title":"J Transl Med"},{"issue":"6","key":"10271_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/17512433.2020.1772052","volume":"13","author":"F Patel","year":"2020","unstructured":"Patel F, Hess DK, Maher DP. Anti-nerve growth factor antibodies for the treatment of low back pain. Expert Rev Clin Pharmacol. 2020;13(6):631\u20139. https:\/\/doi.org\/10.1080\/17512433.2020.1772052.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 1","key":"10271_CR39","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.joca.2014.10.003","volume":"23","author":"TJ Schnitzer","year":"2015","unstructured":"Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015;23(Suppl 1):S8\u201317. https:\/\/doi.org\/10.1016\/j.joca.2014.10.003.","journal-title":"Osteoarthritis Cartilage"},{"issue":"12","key":"10271_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/AJP.0000000000000986","volume":"37","author":"B Zhang","year":"2021","unstructured":"Zhang B, Tian X, Qu Z, Liu J, Yang L. Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review and Meta-analysis of Randomized-Controlled Trials. Clin J Pain. 2021;37(12):914\u201324. https:\/\/doi.org\/10.1097\/AJP.0000000000000986.","journal-title":"Clin J Pain"},{"key":"10271_CR41","doi-asserted-by":"publisher","first-page":"1759720X2110676","DOI":"10.1177\/1759720X211067639","volume":"14","author":"D Zhao","year":"2022","unstructured":"Zhao D, Luo MH, Pan JK, et al. Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2022;14:1759720X211067639. https:\/\/doi.org\/10.1177\/1759720X211067639. Published 2022 Jan 19.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10271_CR42","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s10067-024-07292-w","volume":"44","author":"H Kou","year":"2025","unstructured":"Kou H, Chen B. Standardized efficacy and safety evaluation of fulranumab for osteoarthritis. Clin Rheumatol. 2025;44:1417\u201326. https:\/\/doi.org\/10.1007\/s10067-024-07292-w.","journal-title":"Clin Rheumatol"},{"key":"10271_CR43","doi-asserted-by":"publisher","unstructured":"Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaver C, Dodge C, Felson D, Gellar K, Harvey WF, Hawker G, Herzig E, Kwoh CK, Nelson AE, Samuels J, Scanzello C, White D, Wise B, Altman RD, DiRenzo D, Fontanarosa J, Giradi G, Ishimori M, Misra D, Shah AA, Shmagel AK, Thoma LM, Turgunbaev M, Turner AS, Reston J. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220\u2013233. https:\/\/doi.org\/10.1002\/art.41761.","DOI":"10.1002\/art.41761"},{"issue":"1","key":"10271_CR44","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.18632\/aging.202232","volume":"13","author":"Z Cao","year":"2020","unstructured":"Cao Z, Zhou J, Long Z, Liu F, Lv Y, Yang H, et al. Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs. Aging. 2020;13(1):1051\u201370. https:\/\/doi.org\/10.18632\/aging.202232.","journal-title":"Aging"},{"key":"10271_CR45","doi-asserted-by":"publisher","unstructured":"Katz JN, Smith SR, Collins JE et al. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthritis and Cartilage. 2016;24:409\u2013418. https:\/\/doi.org\/10.1016\/j.joca.2015.10.006Imrey. (2020).","DOI":"10.1016\/j.joca.2015.10.006Imrey"},{"key":"10271_CR46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. CJASN. 2017;12:332\u201345. https:\/\/doi.org\/10.2215\/CJN.05000516.","journal-title":"CJASN"},{"key":"10271_CR47","doi-asserted-by":"publisher","first-page":"5706359","DOI":"10.1155\/2016\/5706359","volume":"2016","author":"S Takano","year":"2016","unstructured":"Takano S, Uchida K, Miyagi M, et al. Nerve Growth Factor Regulation by TNF-\u03b1 and IL-1\u03b2 in Synovial Macrophages and Fibroblasts in Osteoarthritic Mice. J Immunol Res. 2016;2016:5706359.","journal-title":"J Immunol Res"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-026-10271-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-026-10271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-026-10271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:36:42Z","timestamp":1792467402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-026-10271-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10271"],"URL":"https:\/\/doi.org\/10.1186\/s12891-026-10271-8","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable for systematic review.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"888"}}